文献速递先天性心脏病外科瓣膜外科

BioIntegral可注射肺动脉瓣置换的中长期随访

Mid- to long-term follow-up of pulmonary valve replacement with BioIntegral injectable valve.
PubMed 文献 · Eur J Cardiothorac Surg · 2020-11-19

该研究基于国际注册数据,评估85例有症状的严重肺动脉瓣反流或狭窄患者接受可注射支架肺动脉瓣置换的中长期临床结局。平均随访4.8年,显示右心室尺寸显著缩小、跨瓣压差低,总体死亡率2.3%,瓣膜相关并发症少见,中期耐久性和血流动力学表现良好。

要点

  • 可注射肺动脉瓣可在无需体外循环下植入,减少手术对心功能的影响。
  • 中长期随访显示右心室尺寸显著缩小,跨瓣压差低,血流动力学表现优良。
  • 总体死亡率2.3%,感染性心内膜炎罕见,6%患者出现肺动脉瓣狭窄。

核心结论

  • 可注射肺动脉瓣可在杂交手术室中无需体外循环植入,手术创伤小。
  • 该生物瓣膜中期耐久性结果令人鼓舞,中长期血流动力学表现优良。

研究设计与样本

  • 回顾性注册研究,纳入2007年4月至2019年10月共85例有症状的严重肺动脉瓣反流或狭窄患者。
  • 患者平均年龄26.7岁,69.4%为法洛四联症修复术后,72.9%存在中重度肺动脉瓣反流。
  • 25.9%患者采用非体外循环植入,53%患者同期修复其他心脏缺损。

主要发现

  • 术后轻微并发症发生率为10.8%,总体死亡率为2.3%,死亡与严重心功能不全相关。
  • 1例患者因感染性心内膜炎取出瓣膜,6%患者出现肺动脉瓣狭窄。
  • 平均随访4.8年(2个月至12.7年),42%患者随访超过5年。
  • 随访超声心动图和心脏磁共振显示右心室尺寸显著缩小,肺动脉瓣跨瓣压差低。

临床怎么用

  • 对于法洛四联症修复术后等先心病患者,可考虑使用可注射肺动脉瓣行肺动脉瓣置换。
  • 该瓣膜无需缝合环,可植入相对较大尺寸,避免右心室流出道梗阻。
  • 该装置为未来可能的经皮瓣中瓣手术预留了条件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Chronic pulmonary valve (PV) regurgitation is a common late sequela after repair of congenital heart diseases like tetralogy of Fallot or pulmonary stenosis, leading to right ventricular dilatation and failure and increased late morbidity and mortality. Timely reoperation may lead to a complete right ventricular recovery. An injectable PV allows pulmonary valve replacement, with or without cardiopulmonary bypass, under direct observation, thereby minimizing the impact of surgery on cardiac function. The aim of this study was to evaluate the feasibility and mid- to long-term clinical outcomes with this device. METHODS: From April 2007 to October 2019, a total of 85 symptomatic patients with severe pulmonary regurgitation or pulmonary stenosis underwent pulmonary valve replacement with an injectable stented pulmonary prosthesis. Data were collected from the international proctoring registry. Mean patient age was 26.7 years. The underlying diagnosis was repaired tetralogy of Fallot in 69.4% patients; moderate or severe pulmonary regurgitation was present in 72.9%. All patients had echocardiographic scans before the operation and during the follow-up period. A total of 54.1% patients also had preoperative/postoperative cardiac magnetic resonance imaging (MRI) or catheterization; 25.9% had off-pump implants. In 53% patients, pulmonary valve replacement was associated with the repair of other cardiac defects. RESULTS: Minor postoperative complications were observed in 10.8% patients. The overall mortality rate was 2.3%; mortality after valve replacement was linked to a severe cardiac insufficiency and it was not related to a prosthesis failure; 1 prosthesis was explanted from 1 patient because of endocarditis, and 6% of patients developed PV stenosis; minor complications occurred in 4.8%. The mean follow-up period was 4.8 years (2 months-12.7 years); 42% of the patients were followed for more than 5 years. Follow-up echocardiography and cardiac MRI showed a significant reduction in RV size and low gradients across the PV. CONCLUSIONS: An injectable PV may be implanted without cardiopulmonary bypass and in a hybrid operating theatre with minimal surgical impact. The bioprosthesis, available up to large sizes, has a low profile, laminar flow and no risk of coronary artery compression. Incidence of endocarditis is rare. The lack of a suture ring permits the implant of a relatively larger prosthesis, thereby avoiding a right ventricular outflow tract obstruction. This device permits future percutaneous valve-in-valve procedures, if needed. Results concerning durability are encouraging, and mid- to long-term haemodynamic performance is excellent.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Ghiselli S, Carro C, Uricchio N, et al. Mid- to long-term follow-up of pulmonary valve replacement with BioIntegral injectable valve. Eur J Cardiothorac Surg. 2020. PMID: 33210126. doi:10.1093/ejcts/ezaa337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。